STOCK TITAN

TWST Form 4: COO Patrick Finn reports 79,785-share PSU award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience (TWST): insider equity award update. President and COO Patrick John Finn acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an “A” (acquisition). Following this transaction, he beneficially owns 286,280 shares directly. The shares reflect Performance Stock Units for which target criteria were determined to have been met on October 28, 2025. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided in the award agreement.

Positive

  • None.

Negative

  • None.

Insights

Routine Form 4: PSU milestone met; partial vesting scheduled.

Patrick John Finn, President and COO of Twist Bioscience, reported an acquisition of 79,785 common shares at $0 on October 28, 2025, tied to Performance Stock Units reaching their target. His direct beneficial ownership stands at 286,280 shares after the transaction.

The filing notes that 60% of the PSUs remain subject to time-based vesting, scheduled to vest on October 1, 2026, subject to continued service or acceleration under the award agreement. This is a standard equity compensation mechanism and does not, by itself, indicate a change in business outlook.

Future share delivery depends on service conditions and any acceleration provisions in the award. Actual impact on share count depends on the vesting and settlement of remaining PSUs per the stated schedule.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Finn Patrick John

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/28/2025 A 79,785(1) A $0 286,280 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn 10/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TWST report for Patrick John Finn?

He acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an acquisition tied to PSUs meeting targets.

How many TWST shares does Patrick John Finn own after the transaction?

He beneficially owns 286,280 shares directly following the reported acquisition.

What triggered the TWST share acquisition reported on Form 4?

Target criteria for Performance Stock Units were determined to have been met on October 28, 2025.

What is the vesting schedule for the remaining TWST PSUs?

60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement.

What is Patrick John Finn’s role at TWST?

He is the company’s President and COO.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.53B
59.50M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO